

Ant nia Agust-

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9380868/publications.pdf>

Version: 2024-02-01

34
papers

901
citations

759233

12
h-index

501196

28
g-index

39
all docs

39
docs citations

39
times ranked

1546
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan. Expert Opinion on Biological Therapy, 2022, 22, 831-842.	3.1	2
2	Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study. Diagnostics, 2022, 12, 1612.	2.6	3
3	Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 2021, 27, 475-478.	3.0	16
4	A case series of confusional states and other neurotoxic effects caused by ertapenem. British Journal of Clinical Pharmacology, 2021, 87, 2140-2145.	2.4	5
5	Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments. British Journal of Clinical Pharmacology, 2021, 87, 2549-2557.	2.4	3
6	Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy, 2021, 23, 261-274.	0.7	33
7	Integrated health intervention on polypharmacy and inappropriate prescribing in elderly people with multimorbidity: Results at the end of the intervention and at 6 months after the intervention. Medicina Clínica, 2021, 156, 263-269.	0.6	3
8	Integrated health intervention on polypharmacy and inappropriate prescribing in elderly people with multimorbidity: Results at the end of the intervention and at 6 months after the intervention. Medicina Clínica (English Edition), 2021, 156, 263-269.	0.2	0
9	Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service. Frontiers in Pharmacology, 2021, 12, 670945.	3.5	4
10	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	13.7	316
11	Spontaneously Reported Adverse Drug Reactions and Their Description in Hospital Discharge Reports: A Retrospective Study. Journal of Clinical Medicine, 2021, 10, 3293.	2.4	3
12	Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study. Journal of Clinical Medicine, 2021, 10, 4941.	2.4	1
13	Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union. Frontiers in Pharmacology, 2021, 12, 773712.	3.5	9
14	Current landscape of clinical development and approval of advanced therapies. Molecular Therapy - Methods and Clinical Development, 2021, 23, 606-618.	4.1	21
15	Adverse Drug Reactions in Pediatric Oncohematology: A Systematic Review. Frontiers in Pharmacology, 2021, 12, 777498.	3.5	3
16	Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. Vaccines, 2021, 9, 1463.	4.4	8
17	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. Enfermedades Infecciosas Y Microbiología Clínica, 2020, , .	0.5	4
18	Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Frontiers in Pharmacology, 2019, 10, 921.	3.5	111

#	ARTICLE	IF	CITATIONS
19	Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries. <i>Frontiers in Pharmacology</i> , 2019, 10, 1279.	3.5	12
20	Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1384-1388.	2.4	10
21	Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study. <i>Drugs and Aging</i> , 2017, 34, 453-466.	2.7	20
22	Impact of Implementing a Protocol on the Perioperative Management in Patients Treated with Antithrombotics Admitted for Hip Fracture Surgery: an Observational Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 476-484.	2.5	2
23	Polypharmacy in elderly people with diabetes admitted to hospital. <i>Acta Diabetologica</i> , 2016, 53, 857-858.	2.5	3
24	Elderly patients treated with psychotropic medicines admitted to hospital: associated characteristics and inappropriate use. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 755-764.	1.9	11
25	Inappropriate prescribing to the oldest old patients admitted to hospital: prevalence, most frequently used medicines, and associated factors. <i>BMC Geriatrics</i> , 2015, 15, 42.	2.7	67
26	The importance of reporting suspected adverse reactions caused by new drugs. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1478-1479.	3.0	0
27	An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool. <i>Archives of Gerontology and Geriatrics</i> , 2014, 58, 460-464.	3.0	11
28	Inappropriate prescribing to older patients admitted to hospital: A comparison of different tools of misprescribing and underprescribing. <i>European Journal of Internal Medicine</i> , 2014, 25, 710-716.	2.2	47
29	Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 937-945.	1.9	24
30	Educational sessions in pharmacovigilance: What do the doctors think?. <i>BMC Research Notes</i> , 2010, 3, 311.	1.4	6
31	Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 569-581.	1.4	40
32	An Intervention to Improve Spontaneous Adverse Drug Reaction Reporting by Hospital Physicians. <i>Drug Safety</i> , 2009, 32, 77-83.	3.2	67
33	Novedades en el tratamiento de la insuficiencia cardíaca. <i>Atencion Primaria</i> , 2006, 38, 107-115.	1.4	1
34	Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction. <i>Drug Safety</i> , 2003, 26, 895-908.	3.2	21